Skip to main content
SpringerLink
Log in

Afatinib/erlotinib

Emergence of drug resistance: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Jiang H, et al. EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma. Lung Cancer 145: 216-218, Jul 2020. Available from: URL: http://doi.org/10.1016/j.lungcan.2020.04.001

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Afatinib/erlotinib. Reactions Weekly 1818, 17 (2020). https://doi.org/10.1007/s40278-020-82297-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-82297-2

Search

Navigation